Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
This is used to treat central diabetes insipidus and bedwetting
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
Subscribe To Our Newsletter & Stay Updated
